Natural history of hepatitis C following liver transplantation

Current Opinion in Infectious Diseases

Volumn 17, Issue 4, 2004, Pages 363-371

  Rodriguez Luna, Hector ^a   Douglas, David D ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

Acute cellular rejection; Fibrosing cholestatic hepatitis; Hepatitis C; Hepatocellular carcinoma; Interferon; Liver transplantation; Living donor liver transplant; Ribavirin; Selective serotonin re uptake inhibitor; Sustained viral response

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ACUTE GRAFT REJECTION; BIOCHEMICAL COMPOSITION; BONE MARROW SUPPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG TOLERANCE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; NONHUMAN; ORGAN DONOR; POPULATION MODEL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT FAILURE; VIROLOGY;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERONS; LIVER TRANSPLANTATION; RIBAVIRIN;

EID: 3843066657     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000136934.06039.01     Document Type: Review

References (96)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S-65S.
2. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36:227-242.
3. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20:1-16.
4. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9:331-338. Epidemiological study projecting the impact of chronic HCV infection in the USA over the next 40 years.
5. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999; 29:1220-1226.
6. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815-820.
7. Prieto M, Berenguer M, Rimola A, et al. Liver transplantation in hepatitis C: a Spanish multi-centre experience. Eur J Gastroenterol Hepatol 1998; 10:771-776.
8. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103:317-322.
9. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167-177.
10. Guerrero RB, Batts KP, Burgart LJ, et al. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000; 13:229-237.
11. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32:1125-1130.
12. Gretch DR, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995; 22:1-9.
13. Zhou S, Terrault NA, Ferrell L, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996; 24:1041-1046.
14. Konig V, Bauditz J, Lobeck H, et al. Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. Hepatology 1992; 16:1137-1143.
15. Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106:994-999.
16. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002; 8:S7-S13.
17. Ballardini G, De Raffele E, Groff P, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002; 8:10-20.
18. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9:S1-S9. Recommendations of the first international expert panel on recurrence of HCV infection, outcome, risk factors, and treatment.
19. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680-687.
20. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896.
21. Pelletier SJ, Iezzoni JC, Crabtree TD, et al. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000; 6:44-53.
22. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29:250-256.
23. Slapak GI, Saxena R, Portmann B, et al. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 1997; 25:195-202.
24. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202-210.
25. Berenguer M, Rayon JM, Prieto M, et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001; 7:790-796.
26. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117:619-625.
27. Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73:56-63.
28. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
29. Feray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:1137-1143.
30. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32:852-858.
31. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35:666-678.
32. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7:811-815.
33. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-472.
34. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823-830.
35. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998; 4:15-21.
36. Zekry A, Bishop GA, Bowen DG, et al. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl 2002; 8:292-301.
37. Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23:971-976.
38. Dickson RC, Caldwell SH, Ishitani MB, et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996; 61:701-705.
39. McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl Infect Dis 2000; 2:166-185.
40. Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl 2003; 9:S48-S51.
41. Pessoa MG, Bzowej N, Berenguer M, et al. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999; 30:1513-1520.
42. Rosen HR, Hinrichs DJ, Gretch DR, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117:926-932.
43. Schirren CA, Jung MC, Gerlach JT, et al. Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology 2000; 32:597-603.
44. Weinstein JS, Poterucha JJ, Zein N, et al. Epidemiology and natural history of hepatitis C infections in liver transplant recipients. J Hepatol 1995; 22:154-159.
45. Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl 2002; 8:814-821.
46. Cotler SJ, Ganger DR, Kaur S, et al. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation 2001; 71:261-266.
47. Gotz G, Schon MR, Haefker A, et al. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin. Transplant Proc 1998; 30:2104-2106.
48. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:30-34.
49. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51:248-252.
50. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362-369.
51. Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117:149-153.
52. Chopra KB, Demetris AJ, Blakolmer K, et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003; 76:1487-1491.
53. Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8:884-888.
54. Taniguchi MWM, Bak T, Trotter J, et al. Hepatitis C recurrence in living donor liver transplantation. Am J Transpl 2002; 3S:3A.
55. Rodriguez-Luna H, Vargas HE, Sharma P, et al. Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci 2004; 49:38-41.
56. Shiffman MFR, Stravitz RT, Luketic VA, et al. Histologic analysis of recurrent hepatitis C virus infection following living donor and cadaveric liver transplantation. Am J Transpl 2003; S5(3A):203.
57. Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003; 9:1129-1144.
58. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350-355.
59. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9:S90-S94. Review and recommendations for the treatment of patients with end-stage liver disease and cirrhosis before liver transplantation.
60. Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003; 7:585-602.
61. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
62. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
63. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-1457.
64. Fukumoto T, Berg T, Ku Y, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996; 24:1351-1354.
65. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22:1084-1089.
66. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27:1403-1407.
67. Singh N, Gayowski T, Wannstedt CF, Marino IR, Wagener MM. Interferon-alpha therapy for hepatitis C virus recurrence after liver transplantation: long-term response with maintenance therapy. Clin Transplant 1996; 10:348-351.
68. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25:591-598.
69. Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:773-779.
70. Wright HI, Gavaler JS, Van Theil DH. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53:121-124.
71. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500-504.
72. Gane EJ, Tibbs CJ, Ramage JK, et al. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995; 8:61-64.
73. Quadri R, Giostra E, Roskams T, et al. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation 2002; 73:373-378.
74. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
75. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77:190-194.
76. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124:642-650.
77. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8:623-629.
78. Neuberger J. Treatment of hepatitis C virus infection in the allograft. Liver Transpl 2003; 9:S101-S108. Review of different strategies for treatment of post-liver transplant HCV infection along with recommendations for treatment.
79. Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003; 9:348-353.
80. Wall WJ, Khakhar A. Retransplantation for recurrent hepatitis C: the argument against. Liver Transpl 2003; 9:S73-S78.
81. Ghobrial RM, Farmer DG, Baquerizo A, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999; 229:824-831; discussion 831-833.
82. Ghobrial RM. Retransplantation for recurrent hepatitis C. Liver Transpl 2002; 8:S38-S43.
83. Sheiner PA, Schluger LK, Emre S, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997; 3:130-136.
84. Markmann JF, Markowitz JS, Yersiz H, et al. Long-term survival after retransplantation of the liver. Ann Surg 1997; 226:408-418; discussion 418-420.
85. Doyle HR, Morelli F, McMichael J, et al. Hepatic retransplantation: an analysis of risk factors associated with outcome. Transplantation 1996; 61:1499-1505.
86. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66:1612-1616.
87. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
88. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34:1193-1199.
89. Pol S, Lamorthe B, Thi NT, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998; 28:945-950.
90. Bouscarat F, Samuel D, Simon F, et al. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994; 19:854-859.
91. Tzakis AG, Cooper MH, Dummer JS, et al. Transplantation in HIV+ patients. Transplantation 1990; 49:354-338.
92. Gow PJ, Pillay D, Mutimer D. Solid organ transplantation in patients with HIV infection. Transplantation 2001; 72:177-181.
93. Soriano V, Valencia E, Laguna F, Gonzalez-Lahoz J. High morbidity and mortality associated with non-AIDS defining conditions in HIV-infected patients in Spain. Genitourin Med 1994; 70:355-356.
94. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9:239-247. Multicenter report of post-liver-transplant outcome of patients with HIV/HCV coinfection.
95. Neuberger J. Should liver transplantation be made available to everyone? The case against. Arch Intern Med 2003; 163:1881-1883.
96. Douglas DD. Should everyone have equal access to organ transplantation? An argument in favor. Arch Intern Med 2003; 163:1883-1886.